“We are excited to share our modeling analysis on the Cost of Goods for the manufacturing of Molnupiravir, a critical, life-saving COVID-19 therapeutic. The paper is a result of collaboration …
Pharmaceutical and medical device companies operating in the U.S. must comply with strict Good Manufacturing Practices (GMPs) to ensure public safety, efficacy, and product quality. Yet, despite rigorous internal controls, …
Sia/LBG’s Andrew B. Harmon, a recognized subject matter expert providing strategic insights across the biopharmaceutical industry, recently presented a forward-looking model for the viral vector market at BioProcess International Europe …
We are proud to share that Patrick Falvey, Principal Consultant at Latham BioPharma Group (LBG), was featured in the American Pharmaceutical Review! In his interview, published on October 1, 2024, …
Cytokines have long been recognized for their potential in cancer immunotherapy, but achieving clinical success has remained a challenge. The recently published research article, “SON-1010: an albumin-binding IL-12 fusion protein …
We are excited to announce that LBG’s Robert Huebner will be speaking at the upcoming World Vaccine Congress Europe 2024! Robert will be presenting on the topic, “New Technologies for …
LBG’s Andrew Harmon is speaking at the BioProcess Insider’s State of the Industry Discussion. This discussion is being presented at BPI East 2024 in Boston. This engaging session will cover …
Georgia Sloboda, LBG’s Managing Director of Chemistry Manufacturing & Controls, will be presenting at the Bioprocessing Venture, Innovation & Partnering Conference on August 21st in Boston. Her topic, the Challenges …
“Sustainable manufacturing aims to improve on current manufacturing processes and create a far more ecologically friendly system without sacrificing productivity,” states Latham BioPharm Group, part of Sia Partners Patrick Falvey. …
Georgia Sloboda, Managing Director, CMC at LBG was recently recognized by The Corporate Magazine for her leadership expertise.